AGENTURMELDUNGEN |
|---|
13:59 | 28.09.2010
PRESS RELEASE: HUGIN AD-HOC/Q-Cells SE:Ad hoc: ABO placement completed successfully – subscription price for rights issue set at 2.16 Euro per new share
PRESS RELEASE: HUGIN AD-HOC/Q-Cells SE:Ad hoc: ABO placement completed successfully – subscription price for rights issue set at 2.16 Euro per new share
Q-Cells SE / / Ad hoc: ABO placement completed successfully - subscription price for rights issue set at 2.16 Euro per new share processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Bitterfeld-Wolfen, 28 September 2010 - The Board of Q-Cells SE has now
determined the key terms of the rights issue. The subscription price for the
58.765.955 new bearer shares is set at 2.16 Euro per share.
Prior to this decision 9.9 million new ex rights bearer shares based on
subscription rights held by Good Energies (Solar Investments) S.à r.l.,
Luxemburg, had been placed by way of an Accelerated Bookbuilt Offering (ABO)
with institutional investors without subscription rights at a price of 3.60 Euro
per share. The subscription price for new shares is 40% lower than the ABO
price. The subscription period for new shares, which will commence tomorrow,
will run until the end of 12 October 2010. Net proceeds to Q-Cells SE from the
rights issue pursuant to the offer conditions as stated will amount to
approximately up to 120 million Euro if all bearer shares can be placed.
It is envisaged that the shares placed under the Accelerated Bookbuilt Offering
will be included in the existing trading in the Prime Standard market segment of
the Frankfurt Stock Exchange by 1 October 2010, and delivery and settlement of
these shares under the Accelerated Bookbuilt Offering will occur on 4 October
2010. Delivery and settlement of the new shares pursuant to the rights issue is
envisaged for 14 October 2010. At this time it is also planned to include the
new shares in trading in the Prime Standard market segment of the Frankfurt
Stock Exchange.
The subscription period for the new convertible bond and the repurchase offer
for the outstanding convertible bond 2007/2012 will commence at the same time as
the subscription period for the rights issue.
Contact information:
Q-Cells SE
OT Thalheim
Sonnenallee 17 - 21
06766 Bitterfeld-Wolfen, Germany
www.q-cells.com
Investor Relations:
Stefan Lissner
Phone: +49 (0)3494 - 6699 10101
investor@q-cells.com
Corporate Communications:
Ina von Spies
Phone: +49 (0)3494 - 6699 10121
presse@q-cells.com
Disclaimer
This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) to investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order (all such persons together being
referred to as "relevant persons"). The securities are only available to, and
any invitation, offer or agreement to subscribe for, purchase or otherwise
acquire such securities will be engaged in only with, relevant persons. Any
person who is not a relevant person should not act or rely on this document or
any of its contents.
Stabilisation/Regulation (EC) 2273/2003 and FSA.
This document is an advertisement for the purposes of applicable measures
implementing Directive 2003/71/EC (such Directive, together with any applicable
implementing measures in the relevant home Member State under such Directive,
the "Prospectus Directive"). A prospectus prepared pursuant to the Prospectus
Directive is expected to be published on 28 September 2010, following approval
by the German Federal Financial Supervisory Authority, the prospectus can be
obtained from Q-Cells SE, OT Thalheim, Sonnenallee 17-21, 06766
Bitterfeld-Wolfen, Germany.
In any EEA Member State other than Germany that has implemented Directive
2003/71/EC (together with any applicable implementing measures in any Member
State, the "Prospectus Directive") this communication is only addressed to and
directed at qualified investors in that Member State within the meaning of the
Prospectus Directive.
This notification does not constitute a prospectus. Only the prospectus contains
the information for investors required pursuant to the legal requirements. The
German version of the prospectus was published on 28 September 2010 and is
available free of charge on the website of Q-Cells SE (www.q-cells.de) and on
request in printed form from Q-Cells SE, OT Thalheim, Sonnenallee 17-21, 06766
Bitterfeld-Wolfen.
[HUG#1447316]
--- End of Message ---
Q-Cells SE
OT Thalheim, Sonnenallee 17-21 Bitterfeld-Wolfen Germany
WKN: 555866;ISIN: DE0005558662;Index:TecDAX,Prime All Share,CDAX,GEX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Q-Cells SE via Thomson Reuters ONE
http://www.q-cells.com
(END) Dow Jones Newswires September 28, 2010 07:59 ET (11:59 GMT) |
| Weitere Meldungen |
|---|